MovDisordV3, PascalFrancis, Corpus, bibRecord, 001F69

Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia

Identifieur interne : 001F69 ( PascalFrancis/Corpus ); précédent : 001F68; suivant : 001F70

Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia

Auteurs : Brian Berman ; Lauren Seeberger ; Rajeev Kumar

Source :

Movement disorders [ 0885-3185 ] ; 2005.

RBID : Pascal:05-0150408

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Long terme, Sécurité, Dystonie, Bontoxilysin, Contrôle moteur.

English descriptors

KwdEn :
- Bontoxilysin, Dystonia, Long term, Motor control, Nervous system diseases, Safety.

Abstract

Short-term studies of cervical dystonia (CD) have demonstrated botulinum toxin type B (Bot B) to be safe and efficacious at doses of 5,000 to 10,000 units, but few long-term studies have been published and the safety and efficacy of higher doses has not been established. Additionally, there are few studies describing the development of resistance to Bot B in those with and without prior resistance to botulinum toxin type A (Bot A). We reviewed our experience with 24 patients treated with Bot B for up to 64 months. Patients were treated with Bot B for 26.2 ± 20.4 months (range, 3-64 months) with a mean treatment dose of 14,828 ± 6,824 units (range, 2,500-28,000 units). At last follow-up, 12 patients demonstrated ongoing benefit, 8 patients had become secondarily resistant, and 4 patients were primary nonresponders possibly due to the severity and nature of their CD. Nine of the 12 continued responders and 7 of the 8 secondary nonresponders to Bot B had prior probable or definite clinical resistance to Bot A. No severe adverse events related to Bot B were seen. Treatment of patients with severe CD who continue to show a beneficial response to Bot B injections commonly requires doses of 15,000 units and rarely greater than 20,000 units. Patients may continue to respond for up to 64 months. Prior Bot A resistance may be a risk factor for the development of resistance to Bot B; nevertheless, Bot B can be a useful long-term alternative in some Bot A-resistant CD patients.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 20`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia`
A11	`01`	`1`		`@1 BERMAN (Brian)`
A11	`02`	`1`		`@1 SEEBERGER (Lauren)`
A11	`03`	`1`		`@1 KUMAR (Rajeev)`
A14	`01`			`@1 University of Colorado School of Medicine @2 Denver, Colorado @3 USA @Z 1 aut.`
A14	`02`			`@1 Colorado Neurological Institute @2 Englewood, Colorado @3 USA @Z 2 aut. @Z 3 aut.`
A20				`@1 233-237`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000126378730160`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 9 ref.`
A47	`01`	`1`		`@0 05-0150408`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Short-term studies of cervical dystonia (CD) have demonstrated botulinum toxin type B (Bot B) to be safe and efficacious at doses of 5,000 to 10,000 units, but few long-term studies have been published and the safety and efficacy of higher doses has not been established. Additionally, there are few studies describing the development of resistance to Bot B in those with and without prior resistance to botulinum toxin type A (Bot A). We reviewed our experience with 24 patients treated with Bot B for up to 64 months. Patients were treated with Bot B for 26.2 ± 20.4 months (range, 3-64 months) with a mean treatment dose of 14,828 ± 6,824 units (range, 2,500-28,000 units). At last follow-up, 12 patients demonstrated ongoing benefit, 8 patients had become secondarily resistant, and 4 patients were primary nonresponders possibly due to the severity and nature of their CD. Nine of the 12 continued responders and 7 of the 8 secondary nonresponders to Bot B had prior probable or definite clinical resistance to Bot A. No severe adverse events related to Bot B were seen. Treatment of patients with severe CD who continue to show a beneficial response to Bot B injections commonly requires doses of 15,000 units and rarely greater than 20,000 units. Patients may continue to respond for up to 64 months. Prior Bot A resistance may be a risk factor for the development of resistance to Bot B; nevertheless, Bot B can be a useful long-term alternative in some Bot A-resistant CD patients.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B02C`
C02	`03`	`X`		`@0 002B17H`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Long terme @5 02`
C03	`02`	`X`	`ENG`	`@0 Long term @5 02`
C03	`02`	`X`	`SPA`	`@0 Largo plazo @5 02`
C03	`03`	`X`	`FRE`	`@0 Sécurité @5 03`
C03	`03`	`X`	`ENG`	`@0 Safety @5 03`
C03	`03`	`X`	`SPA`	`@0 Seguridad @5 03`
C03	`04`	`X`	`FRE`	`@0 Dystonie @5 04`
C03	`04`	`X`	`ENG`	`@0 Dystonia @5 04`
C03	`04`	`X`	`SPA`	`@0 Distonía @5 04`
C03	`05`	`X`	`FRE`	`@0 Bontoxilysin @2 FE @2 FR @5 05`
C03	`05`	`X`	`ENG`	`@0 Bontoxilysin @2 FE @2 FR @5 05`
C03	`05`	`X`	`SPA`	`@0 Bontoxilysin @2 FE @2 FR @5 05`
C03	`06`	`X`	`FRE`	`@0 Contrôle moteur @5 25`
C03	`06`	`X`	`ENG`	`@0 Motor control @5 25`
C03	`06`	`X`	`SPA`	`@0 Control motor @5 25`
C07	`01`	`X`	`FRE`	`@0 Metalloendopeptidases @2 FE`
C07	`01`	`X`	`ENG`	`@0 Metalloendopeptidases @2 FE`
C07	`01`	`X`	`SPA`	`@0 Metalloendopeptidases @2 FE`
C07	`02`	`X`	`FRE`	`@0 Peptidases @2 FE`
C07	`02`	`X`	`ENG`	`@0 Peptidases @2 FE`
C07	`02`	`X`	`SPA`	`@0 Peptidases @2 FE`
C07	`03`	`X`	`FRE`	`@0 Hydrolases @2 FE`
C07	`03`	`X`	`ENG`	`@0 Hydrolases @2 FE`
C07	`03`	`X`	`SPA`	`@0 Hydrolases @2 FE`
C07	`04`	`X`	`FRE`	`@0 Enzyme @2 FE`
C07	`04`	`X`	`ENG`	`@0 Enzyme @2 FE`
C07	`04`	`X`	`SPA`	`@0 Enzima @2 FE`
C07	`05`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 37`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 37`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 37`
C07	`06`	`X`	`FRE`	`@0 Mouvement involontaire @5 38`
C07	`06`	`X`	`ENG`	`@0 Involuntary movement @5 38`
C07	`06`	`X`	`SPA`	`@0 Movimiento involuntario @5 38`
C07	`07`	`X`	`FRE`	`@0 Muscle strié pathologie @5 39`
C07	`07`	`X`	`ENG`	`@0 Striated muscle disease @5 39`
C07	`07`	`X`	`SPA`	`@0 Músculo estriado patología @5 39`
C07	`08`	`X`	`FRE`	`@0 Trouble neurologique @5 40`
C07	`08`	`X`	`ENG`	`@0 Neurological disorder @5 40`
C07	`08`	`X`	`SPA`	`@0 Trastorno neurológico @5 40`
C07	`09`	`X`	`FRE`	`@0 Encéphale pathologie @5 41`
C07	`09`	`X`	`ENG`	`@0 Cerebral disorder @5 41`
C07	`09`	`X`	`SPA`	`@0 Encéfalo patología @5 41`
C07	`10`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 42`
C07	`10`	`X`	`ENG`	`@0 Central nervous system disease @5 42`
C07	`10`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 42`
N21				`@1 101`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 05-0150408 INIST
ET :	Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia
AU :	BERMAN (Brian); SEEBERGER (Lauren); KUMAR (Rajeev)
AF :	University of Colorado School of Medicine/Denver, Colorado/Etats-Unis (1 aut.); Colorado Neurological Institute/Englewood, Colorado/Etats-Unis (2 aut., 3 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2005; Vol. 20; No. 2; Pp. 233-237; Bibl. 9 ref.
LA :	Anglais
EA :	Short-term studies of cervical dystonia (CD) have demonstrated botulinum toxin type B (Bot B) to be safe and efficacious at doses of 5,000 to 10,000 units, but few long-term studies have been published and the safety and efficacy of higher doses has not been established. Additionally, there are few studies describing the development of resistance to Bot B in those with and without prior resistance to botulinum toxin type A (Bot A). We reviewed our experience with 24 patients treated with Bot B for up to 64 months. Patients were treated with Bot B for 26.2 ± 20.4 months (range, 3-64 months) with a mean treatment dose of 14,828 ± 6,824 units (range, 2,500-28,000 units). At last follow-up, 12 patients demonstrated ongoing benefit, 8 patients had become secondarily resistant, and 4 patients were primary nonresponders possibly due to the severity and nature of their CD. Nine of the 12 continued responders and 7 of the 8 secondary nonresponders to Bot B had prior probable or definite clinical resistance to Bot A. No severe adverse events related to Bot B were seen. Treatment of patients with severe CD who continue to show a beneficial response to Bot B injections commonly requires doses of 15,000 units and rarely greater than 20,000 units. Patients may continue to respond for up to 64 months. Prior Bot A resistance may be a risk factor for the development of resistance to Bot B; nevertheless, Bot B can be a useful long-term alternative in some Bot A-resistant CD patients.
CC :	002B17; 002B02C; 002B17H
FD :	Système nerveux pathologie; Long terme; Sécurité; Dystonie; Bontoxilysin; Contrôle moteur
FG :	Metalloendopeptidases; Peptidases; Hydrolases; Enzyme; Extrapyramidal syndrome; Mouvement involontaire; Muscle strié pathologie; Trouble neurologique; Encéphale pathologie; Système nerveux central pathologie
ED :	Nervous system diseases; Long term; Safety; Dystonia; Bontoxilysin; Motor control
EG :	Metalloendopeptidases; Peptidases; Hydrolases; Enzyme; Extrapyramidal syndrome; Involuntary movement; Striated muscle disease; Neurological disorder; Cerebral disorder; Central nervous system disease
SD :	Sistema nervioso patología; Largo plazo; Seguridad; Distonía; Bontoxilysin; Control motor
LO :	INIST-20953.354000126378730160
ID :	05-0150408

Links to Exploration step

Pascal:05-0150408

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia</title>
<author><name sortKey="Berman, Brian" sort="Berman, Brian" uniqKey="Berman B" first="Brian" last="Berman">Brian Berman</name>
<affiliation><inist:fA14 i1="01"><s1>University of Colorado School of Medicine</s1>
<s2>Denver, Colorado</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Seeberger, Lauren" sort="Seeberger, Lauren" uniqKey="Seeberger L" first="Lauren" last="Seeberger">Lauren Seeberger</name>
<affiliation><inist:fA14 i1="02"><s1>Colorado Neurological Institute</s1>
<s2>Englewood, Colorado</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kumar, Rajeev" sort="Kumar, Rajeev" uniqKey="Kumar R" first="Rajeev" last="Kumar">Rajeev Kumar</name>
<affiliation><inist:fA14 i1="02"><s1>Colorado Neurological Institute</s1>
<s2>Englewood, Colorado</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0150408</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0150408 INIST</idno>
<idno type="RBID">Pascal:05-0150408</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001F69</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia</title>
<author><name sortKey="Berman, Brian" sort="Berman, Brian" uniqKey="Berman B" first="Brian" last="Berman">Brian Berman</name>
<affiliation><inist:fA14 i1="01"><s1>University of Colorado School of Medicine</s1>
<s2>Denver, Colorado</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Seeberger, Lauren" sort="Seeberger, Lauren" uniqKey="Seeberger L" first="Lauren" last="Seeberger">Lauren Seeberger</name>
<affiliation><inist:fA14 i1="02"><s1>Colorado Neurological Institute</s1>
<s2>Englewood, Colorado</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kumar, Rajeev" sort="Kumar, Rajeev" uniqKey="Kumar R" first="Rajeev" last="Kumar">Rajeev Kumar</name>
<affiliation><inist:fA14 i1="02"><s1>Colorado Neurological Institute</s1>
<s2>Englewood, Colorado</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bontoxilysin</term>
<term>Dystonia</term>
<term>Long term</term>
<term>Motor control</term>
<term>Nervous system diseases</term>
<term>Safety</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Long terme</term>
<term>Sécurité</term>
<term>Dystonie</term>
<term>Bontoxilysin</term>
<term>Contrôle moteur</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Short-term studies of cervical dystonia (CD) have demonstrated botulinum toxin type B (Bot B) to be safe and efficacious at doses of 5,000 to 10,000 units, but few long-term studies have been published and the safety and efficacy of higher doses has not been established. Additionally, there are few studies describing the development of resistance to Bot B in those with and without prior resistance to botulinum toxin type A (Bot A). We reviewed our experience with 24 patients treated with Bot B for up to 64 months. Patients were treated with Bot B for 26.2 ± 20.4 months (range, 3-64 months) with a mean treatment dose of 14,828 ± 6,824 units (range, 2,500-28,000 units). At last follow-up, 12 patients demonstrated ongoing benefit, 8 patients had become secondarily resistant, and 4 patients were primary nonresponders possibly due to the severity and nature of their CD. Nine of the 12 continued responders and 7 of the 8 secondary nonresponders to Bot B had prior probable or definite clinical resistance to Bot A. No severe adverse events related to Bot B were seen. Treatment of patients with severe CD who continue to show a beneficial response to Bot B injections commonly requires doses of 15,000 units and rarely greater than 20,000 units. Patients may continue to respond for up to 64 months. Prior Bot A resistance may be a risk factor for the development of resistance to Bot B; nevertheless, Bot B can be a useful long-term alternative in some Bot A-resistant CD patients.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>20</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BERMAN (Brian)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SEEBERGER (Lauren)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KUMAR (Rajeev)</s1>
</fA11>
<fA14 i1="01"><s1>University of Colorado School of Medicine</s1>
<s2>Denver, Colorado</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Colorado Neurological Institute</s1>
<s2>Englewood, Colorado</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>233-237</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000126378730160</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>9 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0150408</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Short-term studies of cervical dystonia (CD) have demonstrated botulinum toxin type B (Bot B) to be safe and efficacious at doses of 5,000 to 10,000 units, but few long-term studies have been published and the safety and efficacy of higher doses has not been established. Additionally, there are few studies describing the development of resistance to Bot B in those with and without prior resistance to botulinum toxin type A (Bot A). We reviewed our experience with 24 patients treated with Bot B for up to 64 months. Patients were treated with Bot B for 26.2 ± 20.4 months (range, 3-64 months) with a mean treatment dose of 14,828 ± 6,824 units (range, 2,500-28,000 units). At last follow-up, 12 patients demonstrated ongoing benefit, 8 patients had become secondarily resistant, and 4 patients were primary nonresponders possibly due to the severity and nature of their CD. Nine of the 12 continued responders and 7 of the 8 secondary nonresponders to Bot B had prior probable or definite clinical resistance to Bot A. No severe adverse events related to Bot B were seen. Treatment of patients with severe CD who continue to show a beneficial response to Bot B injections commonly requires doses of 15,000 units and rarely greater than 20,000 units. Patients may continue to respond for up to 64 months. Prior Bot A resistance may be a risk factor for the development of resistance to Bot B; nevertheless, Bot B can be a useful long-term alternative in some Bot A-resistant CD patients.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02C</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17H</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Long terme</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Long term</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Sécurité</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Safety</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Seguridad</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dystonie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dystonia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Distonía</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Contrôle moteur</s0>
<s5>25</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Motor control</s0>
<s5>25</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Control motor</s0>
<s5>25</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Muscle strié pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Striated muscle disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Músculo estriado patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>40</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>42</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>42</s5>
</fC07>
<fN21><s1>101</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 05-0150408 INIST</NO>
<ET>Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia</ET>
<AU>BERMAN (Brian); SEEBERGER (Lauren); KUMAR (Rajeev)</AU>
<AF>University of Colorado School of Medicine/Denver, Colorado/Etats-Unis (1 aut.); Colorado Neurological Institute/Englewood, Colorado/Etats-Unis (2 aut., 3 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2005; Vol. 20; No. 2; Pp. 233-237; Bibl. 9 ref.</SO>
<LA>Anglais</LA>
<EA>Short-term studies of cervical dystonia (CD) have demonstrated botulinum toxin type B (Bot B) to be safe and efficacious at doses of 5,000 to 10,000 units, but few long-term studies have been published and the safety and efficacy of higher doses has not been established. Additionally, there are few studies describing the development of resistance to Bot B in those with and without prior resistance to botulinum toxin type A (Bot A). We reviewed our experience with 24 patients treated with Bot B for up to 64 months. Patients were treated with Bot B for 26.2 ± 20.4 months (range, 3-64 months) with a mean treatment dose of 14,828 ± 6,824 units (range, 2,500-28,000 units). At last follow-up, 12 patients demonstrated ongoing benefit, 8 patients had become secondarily resistant, and 4 patients were primary nonresponders possibly due to the severity and nature of their CD. Nine of the 12 continued responders and 7 of the 8 secondary nonresponders to Bot B had prior probable or definite clinical resistance to Bot A. No severe adverse events related to Bot B were seen. Treatment of patients with severe CD who continue to show a beneficial response to Bot B injections commonly requires doses of 15,000 units and rarely greater than 20,000 units. Patients may continue to respond for up to 64 months. Prior Bot A resistance may be a risk factor for the development of resistance to Bot B; nevertheless, Bot B can be a useful long-term alternative in some Bot A-resistant CD patients.</EA>
<CC>002B17; 002B02C; 002B17H</CC>
<FD>Système nerveux pathologie; Long terme; Sécurité; Dystonie; Bontoxilysin; Contrôle moteur</FD>
<FG>Metalloendopeptidases; Peptidases; Hydrolases; Enzyme; Extrapyramidal syndrome; Mouvement involontaire; Muscle strié pathologie; Trouble neurologique; Encéphale pathologie; Système nerveux central pathologie</FG>
<ED>Nervous system diseases; Long term; Safety; Dystonia; Bontoxilysin; Motor control</ED>
<EG>Metalloendopeptidases; Peptidases; Hydrolases; Enzyme; Extrapyramidal syndrome; Involuntary movement; Striated muscle disease; Neurological disorder; Cerebral disorder; Central nervous system disease</EG>
<SD>Sistema nervioso patología; Largo plazo; Seguridad; Distonía; Bontoxilysin; Control motor</SD>
<LO>INIST-20953.354000126378730160</LO>
<ID>05-0150408</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F69 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001F69 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:05-0150408
   |texte=   Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia

Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri